AACR-NCI-EORTC 2015 -- Tumor cell viability and proliferation is regulated by the balance between tumor self-survival and host elimination mechanisms. There are multiple mechanisms whereby tumors successfully evade host immune cell surveillance, permitting continued growth and proliferation.
Breast cancers are considered poorly immunogenic tumors. However, several approaches utilizing immunotherapies are being undertaken in the clinic to evaluate their potential for improving outcomes. Radiation therapy (RT) is a highly utilized clinical treatment modality in breast cancer.
EORTC-NCI-AACR 2016 -- Preclinical immuno-oncology (I/O) needs identification and refinement of tumor models that recapitulate relevant biological dynamics. We tested several murine models for their response to checkpoint inhibitors like anti-CTLA-4, anti-PD-L1 and anti-PD-1 antibodies and found sensitive, moderately sensitive and insensitive models.
AACR 2016 -- The efficacy of immune-modulating anti-cancer therapeutic antibodies that have been FDA-approved in recent years, such as anti-CTLA-4 and anti-PD-1, has driven growing interest in methods that provide a mechanistic understanding of drug function.
Your product's success depends on optimizing the treatment journey. Learn how a robust strategy can address the obstacles that patients and healthcare providers face and strengthen each patient connection.
